2019
DOI: 10.1136/bcr-2018-227646
|View full text |Cite
|
Sign up to set email alerts
|

Synovial sarcoma in an HIV-positive pregnant woman and review of literature

Abstract: We present a first case of synovial sarcoma in an HIV-positive pregnant woman. This 28-year-old woman was diagnosed with synovial sarcoma, a high-grade malignant soft tissue sarcoma, involving her left thigh during the first trimester of her pregnancy. She underwent surgical treatment in the form of hip disarticulation at 30 weeks’ gestation. She was subsequently delivered by emergency caesarean section (CS) at 34 weeks’ gestation when she presented with wound sepsis and a scan revealed static growth in a smal… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
9
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(9 citation statements)
references
References 19 publications
(22 reference statements)
0
9
0
Order By: Relevance
“…Data regarding ifosfamide use in pregnancy is particularly limited; however, Mir et al's review of ifosfamide use in pregnancy noted oligohydramnios in 5 of the 11 patients given this drug at various doses [1], suggesting this as a potential fetal toxicity and is notable in light of the borderline low AFI observed in our case that developed postifosfamide therapy. Among the cases of synovial sarcoma in pregnancy, two experienced fetal growth restriction [6,9], and one was delivered for oligohydramnios with nonreassuring fetal monitoring [11]. These constellations of findings emphasize the importance of frequent fetal monitoring during treatment in order to detect potential obstetrical complications and modify delivery planning as indicated.…”
Section: Discussionmentioning
confidence: 96%
See 1 more Smart Citation
“…Data regarding ifosfamide use in pregnancy is particularly limited; however, Mir et al's review of ifosfamide use in pregnancy noted oligohydramnios in 5 of the 11 patients given this drug at various doses [1], suggesting this as a potential fetal toxicity and is notable in light of the borderline low AFI observed in our case that developed postifosfamide therapy. Among the cases of synovial sarcoma in pregnancy, two experienced fetal growth restriction [6,9], and one was delivered for oligohydramnios with nonreassuring fetal monitoring [11]. These constellations of findings emphasize the importance of frequent fetal monitoring during treatment in order to detect potential obstetrical complications and modify delivery planning as indicated.…”
Section: Discussionmentioning
confidence: 96%
“…In review of the literature, there have been 13 previous cases on synovial sarcoma associated with pregnancy reported [5][6][7][8][9][10][11][12][13][14][15][16][17][18]. These patients, their treatment, and outcomes are summarized in Table 1.…”
Section: Discussionmentioning
confidence: 99%
“…Synovial sarcoma account for 5-10% of all soft tissue sarcomas. 3,4 Commonly, these tumors arise in the extremities with a propensity to metastasize to the lungs. 3,4 There are no known risk factors for synovial sarcoma.…”
Section: Discussionmentioning
confidence: 99%
“…3,4 Commonly, these tumors arise in the extremities with a propensity to metastasize to the lungs. 3,4 There are no known risk factors for synovial sarcoma. [4][5][6] The standard treatment is wide surgical resection with/without radiotherapy.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation